Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ReShape Lifesciences, Inc. - Common Stock (NQ: RSLS )

2.330 -0.210 (-8.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ReShape Lifesciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
Transactions Continue to Progress and Remain on Track 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
FLEX Technology Designed to Improve the Patient Experience 
From ReShape Lifesciences Inc
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes
Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments for... 
From ReShape Lifesciences Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Dow Rises Over 50 Points; AutoZone Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
Effective as of Commencement of Trading on September 23, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
RSLS Stock Earnings: Reshape Lifesciences Misses Revenue for Q2 2024
RSLS stock results show that Reshape Lifesciences missed on revenue for the second quarter of 2024. 
Via InvestorPlace
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS
From Kahn Swick & Foti, LLC
Via Business Wire
RSLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ReShape Lifesciences Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
From ReShape Lifesciences Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
S&P 500 Down 0.5%; Abercrombie & Fitch Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Moves Lower; Advance Auto Parts Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
Why ReShape Lifesciences Stock Is Moving Higher Wednesday
ReShape Lifesciences reported that it gained approval from the United States Patent and Trademark Office for its application entitled, "Intragastric Device (For Treating Obesity)." In the patent... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Dow Dips Over 300 Points; Dick's Sporting Goods Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Cue Health (HLTH) Stock Down 40% Today?
Cue Health stock is down on Wednesday as HLTH investors react to the healthcare company filing for Chapter 7 bankruptcy relief. 
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.